Nagase Viita Announces New Injectable-Grade Excipients
Nagase Viita Co., Ltd., part of the NAGASE Group, is preparing to launch a new product, SUCROSE SG, in June 2025. This addition expands their range of SOLBIOTE (TM), a line of saccharide-based pharmaceutical excipients, designed to meet the robust demands of the biopharmaceutical industry.
Broadening the SOLBIOTE Product Line
With the introduction of SUCROSE SG, Nagase Viita is enhancing its portfolio which already includes signature products such as TREHALOSE SG and MALTOSE PH. These products are recognized for their exceptional qualities in pharmaceutical applications, particularly in stabilizing biopharmaceutical formulations. SUCROSE SG is expected to further solidify the company's commitment to providing comprehensive solutions for stability in the development of biopharmaceuticals.
Importance of Sucrose in Biopharmaceuticals
Sucrose plays a crucial role in maintaining the integrity of various biopharmaceutical products, especially antibody drugs and lipid nanoparticles (LNPs) that have gained prominence in recent years, particularly with the development of vaccines, including those for COVID-19. The high purity and low endotoxin levels of SUCROSE SG make it an ideal candidate for such applications, ensuring the quality and efficacy of medications.
Sustainability Focus in Production
Nagase Viita has always prioritized sustainability alongside its innovative spirit. The production of SUCROSE SG embodies this commitment; it harnesses environmentally friendly processes that utilize water instead of solvents. This approach not only supports the company's sustainability goals but also aligns with the growing global demand for eco-conscious manufacturing practices.
The SOLBIOTE Brand Vision
The name SOLBIOTE (TM) reflects the essence of its mission, derived from “Sol” meaning sun in Latin and “Bio” indicating biotechnology. This name encapsulates the company’s goal to leverage the benefits of natural products, supported by cutting-edge science to enhance the biopharmaceutical industry. With SUCROSE SG, Nagase Viita aims to offer pharmaceutical excipients that not only meet stringent quality standards but also promote innovation in drug development.
Commitment to Quality and Innovation
Nagase Viita's excipients are crafted to ensure a stable supply for pharmaceutical manufacturers, maintaining a high-quality standard throughout their production. As they prepare for the launch of SUCROSE SG, the company reaffirms its dedication to pioneering solutions that address the needs of the ever-evolving pharmaceutical landscape.
Frequently Asked Questions
What is SUCROSE SG?
SUCROSE SG is a new injectable-grade pharmaceutical excipient set to launch by June 2025, enhancing the SOLBIOTE (TM) product line.
Why is sucrose important in pharmaceuticals?
Sucrose acts as a stabilizer in biopharmaceuticals, helping maintain the quality of products like antibody drugs and vaccines.
How is SUCROSE SG produced sustainably?
Nagase Viita produces SUCROSE SG using environmentally friendly methods that utilize water instead of conventional solvents.
What is the SOLBIOTE (TM) brand?
SOLBIOTE (TM) represents a line of saccharide-based excipients aimed at providing innovative solutions for biopharmaceutical development.
When can we expect SUCROSE SG in the market?
SUCROSE SG is expected to be available by June 2025 as part of Nagase Viita's continued commitment to excellence in pharmaceutical ingredients.
